Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. Its product pipeline includes AVTX-002, an Anti-LIGHT mAb targeting immune-inflammatory diseases, including acute respiratory distress syndrome and moderate-to-severe inflammatory bowel disease; and AVTX-007, an Anti-IL-18 mAb targeting immuno-oncology and immune-inflammatory diseases, including multiple myeloma and Still's disease. The company also engages in developing AVTX-006, a dual mTORc1/c2 inhibitor targeting lymphatic malformations; and AVTX 800 programs (AVTX-801, AVTX-802, and AVTX-803), which are therapeutic doses of monosaccharide therapies for congenital disorders of glycosylation. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.